Secondary Screening Workstations – The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions,… Read More
The New Blockbuster Drugs – Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in… Read More
Protein Biochips – On the threshold of success By Dr Steven Bodovitz and Felicia Gentile With sales of protein biochips set to top $700 million in 2006, we present a current overview of this fast moving technology and the applications for the pharmaceutical industry as a whole. Read More
Nanolitre Dispensing – On the point of delivery By Dr John Comley Precise low-volume liquid handling methodologies are still sought after by those interested in enabling miniaturised HTS. This article reviews the need for nanolitre dispensing and provides a current perspective on those emerging technologies that have the… Read More
Biotechnology, Bioterrorism & Biosecurity By Dr George Poste Advances in genetics and biotechnology offer great promise in the fight against infectious diseases. But the same technologies will also increase the threat from bioterrorism. Governments must accord ‘biosecurity’ a higher priority in defence and foreign… Read More
High throughput genomics and drug discovery – parallel universes or a continuum? By Dr Mark Beggs and Audrey Long HTS has been in place for approximately 10-12 years and has achieved a threeorder of magnitude scale up. Genomics has been in a ‘high throughput’ mode for approximately four… Read More
Cell Based Assays – Seeing the light By Dr Nick Thomas High-context cell assays have the potential to take the pivotal role in the drug discovery process. So what are the features of today’s leading edge cell based assay technologies and where does the future lie?… Read More
The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries; and perhaps healthcare delivery in general; are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Read More
Chemogenomics – A gene family approach to parallel drug discovery By Dr Paul R. Caron, Dr Michael D. Mullican, Dr Robert D. Mashal, Dr Keith P. Wilson, Dr Michael S. Su and Dr Mark A. Murcko Currently available drugs only target around 500 different proteins (4). Recent… Read More
The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat… Read More
Health economic considerations for early drug discovery By Dr Ann-Marie Craig and Dr Lisa Kennedy The use of health economics in early phase development, while not an exact science, can, when conjoined with clinical evidence, be a very valuable information tool enabling companies to identify whether there is… Read More
Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora’s box of intellectual… Read More
Outsourcing life science informatics solutions By Dr Steve Gardner The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that… Read More
High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by… Read More
By Dr Ashok R. Dongre and Dr Stanley A. Hefta The genomic sequencing efforts spawned the field of proteomics by providing the basic blueprint for protein sequences, enabling proteomics to become the contemporary technology for studying the underlying mechanisms of disease. This review… Read More
The Future Role of CROs By John M Hall PhD and Ludo Reynders PhD The increasing reliance by big pharmaceutical companies on CROs presents a mixture of challenges and opportunities for the industry. Given that the majority of customers are global in their reach,… Read More